{ event: "article_read", name: `Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis`, author: ``, tags: `Onkologi | Hudkreft | ALL MATERIELL | Terapiområde | Kutan plateepitelkarsinom | Libtayo | Onkologi`, publication_date: ``, interaction_type: "content" }
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Danny Rischin,1 Nikhil I Khushalani,2 Chrysalyne D Schmults,3 Alexander Guminski ,4 Anne Lynn S Chang,5 Karl D Lewis,6 Annette M Lim,1 Leonel Hernandez-Aya,7 Brett G M Hughes,8 Dirk Schadendorf,9 Axel Hauschild,10 Alesha A Thai,11 Elizabeth Stankevich,12 Jocelyn Booth,12 Suk-Young Yoo,12 Siyu Li,12 Zhen Chen,12 Emmanuel Okoye,12 Chieh-I Chen,12 Vera Mastey,12 Medha Sasane,13 Israel Lowy,12 Matthew G Fury,12 Michael R Migden
